Primary Sjögren's syndrome (pSS) is an autoimmune disorder affecting exocrine glands and characterized in most cases by a rather mild clinical picture. However, a subgroup of pSS patients experience systemic extraglandular involvement leading to a worsening of disease prognosis. Current therapeutic options for the treatment of pSS are mainly empirical, often translated by other autoimmune diseases, and recent systematic reviews have highlighted the lack of evidence-based recommendations for most of the drugs commonly employed in the spectrum of extraglandular involvement. Because of the well-established role of B-lymphocytes in the pathogenesis of pSS, a B-cell targeting therapy may represent a new and intriguing therapeutic approach; in this context, growing evidence suggests that B-cell depletion by rituximab (RTX) is also effective in pSS. Of interest, besides clinical efficacy, RTX also showed biologic effects, consistently affecting the inflammation and the lymphoid organization that occur in target tissue. Moreover, the good results observed in the published trials after RTX treatment in pSS should represent the starting point to develop evidence-based guidelines for the use of biologic therapy in this disease.
MavraganiCPNezosAMoutsopoulosHM. New advances in the classification, pathogenesis and treatment of Sjögren's syndrome. Curr Opin Rheumatol2013; 25: 623–629.
2.
ChristodoulouMIKapsogeorgouEKMoutsopoulosHM. Characteristics of the minor salivary gland infiltrates in Sjögren's syndrome. J Autoimmun2010; 34: 400–407.
3.
SarigulMYazisizVBassorgunCI. The numbers of Foxp3 + Treg cells are positively correlated with higher grade of infiltration at the salivary glands in primary Sjögren's syndrome. Lupus2010; 19: 138–145.
4.
AlunnoABistoniOBartoloniE. IL-17-producing CD4-CD8- T cells are expanded in the peripheral blood, infiltrate salivary glands and are resistant to corticosteroids in patients with primary Sjögren's syndrome. Ann Rheum Dis2013; 72: 286–292.
5.
AlunnoACarubbiFBistoniO. CD4–CD8– T-cells in primary Sjögren's syndrome: Association with the extent of glandular involvement. J Autoimmun2014; 51: 38–43.
6.
NocturneGMarietteX. Advances in understanding the pathogenesis of primary Sjögren's syndrome. Nat Rev Rheumatol2013; 9: 544–556.
7.
Ramos-CasalsMTzioufasAGStoneJH. Treatment of primary Sjögren syndrome: A systematic review. JAMA2010; 304: 452–460.
8.
Ramos-CasalsMBrito-ZerónPSisó-AlmirallABoschXTzioufasAG. Topical and systemic medications for the treatment of primary Sjögren's syndrome. Nat Rev Rheumatol2012; 8: 399–411.
9.
Brito-ZerónPSisó-AlmirallABovéAKostovBABamos-CasalsM. Primary Sjögren syndrome: An update on current pharmacotherapy options and future directions. Expert Opin Pharmacother2013; 14: 279–289.
10.
FazaaABourcierTChatelusE. Classification criteria and treatment modalities in primary Sjögren's syndrome. Expert Rev Clin Immunol2014; 10: 543–551.
CarubbiFAlunnoACiprianiP. Is minor salivary gland biopsy more than a diagnostic tool in primary Sjögren's syndrome? Association between clinical, histopathological, and molecular features: A retrospective study. Semin Arthritis Rheum. Epub ahead of print 15 May 2014. DOI: 10.1016/j.semarthrit.2014.05.
13.
AnolikJHLooneyRJLundFE. Insights into the heterogeneity of human B cells: Diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res2009; 45: 144–158.
14.
TatouliIPTzioufasAG. Pathogenetic aspects of humoral autoimmunity in Sjögren's syndrome. Lupus2012; 21: 1151–1154.
15.
VoulgarelisMTzioufasAG. Pathogenetic mechanisms in the initiation and perpetuation of Sjögren's syndrome. Nat Rev Rheumatol2010; 6: 529–537.
16.
QuartuccioLIsolaMBaldiniC. Biomarkers of lymphoma in Sjögren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: Results of a multicenter study. J Autoimmun2014; 51: 75–80.
17.
PescovitzMD. Rituximab, an anti-CD20 monoclonal antibody: History and mechanism of action. Am J Transplant2006; 6(5 Pt 1): 859–866.
18.
PerosaFPreteMRacanelliVDammaccoF. CD20-depleting therapy in autoimmune diseases: From basic research to the clinic. J Intern Med2010; 267: 260–277.
19.
Devauchelle-PensecVPennecYMorvanJ. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum2007; 57: 310–317.
20.
PijpeJMeijerJMBootsmaH. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome. Arthritis Rheum2009; 60: 3251–3256.
21.
PersJODevauchelleVDaridonC. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum2007; 56: 1464–1477.
22.
MackayFSchneiderP. Cracking the BAFF code. Nat Rev Immunol2009; 9: 491–502.
23.
LahiriAPochardPLe PottierL. The complexity of the BAFF TNF-family members: Implications for autoimmunity. J Autoimmun2012; 39: 189–198.
24.
WildenbergMEvan Helden-MeeuwsenCGvan de MerweJPDrexhageHAVersnelMA. Systemic increase in type I interferon activity in Sjögren's syndrome: A putative role for plasmacytoid dendritic cells. Eur J Immunol2008; 38: 2024–2033.
25.
YouinouPPersJO. Disturbance of cytokine networks in Sjögren's syndrome. Arthritis Res Ther2011; 13: 227.
26.
DarceJRArendtBKWuXJelinekDF. Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol2007; 179: 7276–7286.
27.
AbdulahadWHMeijerJMKroeseFG. B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjögren's syndrome: A double-blind, placebo-controlled study. Arthritis Rheum2011; 63: 1116–1123.
28.
St ClairEWLevesqueMCPrakET. Rituximab therapy for primary Sjögren's syndrome: An open-label clinical trial and mechanistic analysis. Arthritis Rheum2013; 65: 1097–1106.
29.
HamzaNBootsmaHYuvarajS. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy. Ann Rheum Dis2012; 71: 1881–1887.
30.
HershbergUMengWZhangB. Persistence and selection of an expanded B cell clone in the setting of rituximab therapy for Sjögren's syndrome. Arthritis Res Ther2014; 16: R51.
31.
PollardRPAbdulahadWHVissinkA. Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjögren's syndrome: Data from a placebo-controlled clinical trial. Ann Rheum Dis2013; 72: 146–148.
32.
CicciaFGugginoGRizzoA. Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren's syndrome. Rheumatology (Oxford)2014; 53: 1313–1320.
33.
CicciaFGiardinaARizzoA. Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjögren's syndrome. Ann Rheum Dis2013; 72: 782–783.
34.
PollardRPAbdulahadWHBootsmaH. Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjögren's syndrome. Ann Rheum Dis2013; 72: 2028–2050.
35.
SistoMLisiSD'AmoreMLofrumentoDD. Rituximab-mediated Raf kinase inhibitor protein induction modulates NF-κB in Sjögren's syndrome. Immunology. Epub ahead of print 21 March 2014. DOI: 10.1111/imm.12288.
36.
CarubbiFCiprianiPMarrelliA. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: A prospective, multicenter, follow-up study. Arthritis Res Ther2013; 15: R172.
PitzalisCJonesGWBombardieriMJonesSA. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat Rev Immunol2014; 14: 447–462.
39.
HansenAReiterKZiprianT. Dysregulation of chemokine receptor expression and function by B cells of patients with primary Sjögren's syndrome. Arthritis Rheum2005; 52: 2109–2119.
40.
HansenALipskyPEDörnerT. B cells in Sjögren's syndrome: Indications for disturbed selection and differentiation in ectopic lymphoid tissue. Arthritis Res Ther2007; 9: 218.
41.
PereiraJPKellyLMCysterJG. Finding the right niche: B-cell migration in the early phases of T-dependent antibody responses. Int Immunol2010; 22: 413–419.
42.
MeijerJMPijpeJVissinkAKallenbergCGBootsmaH. Treatment of primary Sjögren's syndrome with rituximab: Extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis2009; 68: 284–285.
43.
GottenbergJEGuillevinLLambotteO. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis2005; 64: 913–920.
44.
PijpeJvan ImhoffGWSpijkervetFK. Rituximab treatment in patients with primary Sjögren's syndrome: An open-label phase II study. Arthritis Rheum2005; 52: 2740–2750.
45.
Jousse-JoulinSDevauchelle-PensecVMorvanJ. Ultrasound assessment of salivary glands in patients with primary Sjögren's syndrome treated with rituximab: Quantitative and Doppler waveform analysis. Biologics2007; 1: 311–319.
46.
SerorRSordetCGuillevinL. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis2007; 66: 351–357.
47.
GalarzaCValenciaDTobónGJ. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?Clin Rev Allergy Immunol2008; 34: 124–128.
48.
DassSBowmanSJVitalEM. Reduction of fatigue in Sjögren syndrome with rituximab: Results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis2008; 67: 1541–1544.
49.
Ramos-CasalsMGarcía-HernándezFJde RamónE. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol2010; 28: 468–476.
50.
MeijerJMMeinersPMVissinkA. Effectiveness of rituximab treatment in primary Sjögren's syndrome: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum2010; 62: 960–968.
51.
MeinersPMArendsSBrouwerESpijkervetFKVissinkABootsmaH. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab. Ann Rheum Dis2012; 71: 1297–1302.
52.
TerrierBLaunayDKaplanskiG. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: Data from the French Autoimmunity and Rituximab registry. Arthritis Care Res (Hoboken)2010; 62: 1787–1795.
53.
TonyHPBurmesterGSchulze-KoopsH. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: Experience from a national registry (GRAID). Arthritis Res Ther2011; 13: R75.
54.
MekinianARavaudPLarrocheC. Rituximab in central nervous system manifestations of patients with primary Sjögren's syndrome: Results from the AIR registry. Clin Exp Rheumatol2012; 30: 208–212.
55.
MekinianARavaudPHatronPY. Efficacy of rituximab in primary Sjögren's syndrome with peripheral nervous system involvement: Results from the AIR registry. Ann Rheum Dis2012; 71: 84–87.
56.
GottenbergJECinquettiGLarrocheC. Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: Results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis2013; 72: 1026–1031.
57.
Devauchelle-PensecVMarietteXJousse-JoulinS. Treatment of primary Sjögren syndrome with rituximab: A randomized trial. Ann Intern Med2014; 160: 233–242.
58.
Devauchelle-PensecVMorvanJRatAC. Effects of rituximab therapy on quality of life in patients with primary Sjögren's syndrome. Clin Exp Rheumatol2011; 29: 6–12.
59.
BrownSNavarro CoyNPitzalisC. The TRACTISS protocol: A randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjögren's syndrome. BMC Musculoskelet Disord2014; 15: 21.
60.
SerorRTheanderEBootsmaH. Outcome measures for primary Sjögren's syndrome: A comprehensive review. J Autoimmun2014; 51: 51–56.
61.
MoermanRVArendsSMeinersPM. EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomized controlled trial. Ann Rheum Dis2014; 73: 472–474.
62.
SerorRTheanderEBrunJG. Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis. Epub ahead of print 2014. DOI: 10.1136/annrheumdis-2013-204615.
63.
De VitaSQuartuccioLSalvinS. Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexp[r]ession of BAFF: Evidence for long-term efficacy. Clin Exp Rheumatol2014; 32: 490–494.
